Article

Discovery of Next-Generation Tropomyosin Receptor Kinase (TRK) Inhibitors for Combatting Resistance Associated with Protein Mutation

2021-06-17

Abstract excerpt

Aberrant signaling from tropomyosin receptor kinases (TRKs) has been identified as the oncogenic driver in a large variety of cancers, suggesting that inhibition of TRK may be an attractive strategy of attack for anticancer therapeutics. Despite the encouraging therapeutic response to the first-generation TRK inhibitor Larotrectinib ( 1 ), the emergence of drug-resistant secondary mutations within its ATP-binding...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: feb9dbe9-37d6-5bed-a355-787555394223
DOI: 10.21203/rs.3.rs-597552/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Discovery of Next-Generation Tropomyosin Receptor Kinase (TRK) Inhibitors for Combatting Resistance Associated with Protein MutationDOI 10.21203/rs.3.rs-597552/v1Read

Discovery of Next-Generation Tropomyosin Receptor Kinase Inhibitors for Combating Multiple Resistance Associated with Protein Mutation.Semantic proximity Read

Discovery of imidazo[1,2-b]pyridazine derivatives as potent TRK inhibitors for overcoming multiple resistant mutants.Semantic proximity Read

Structure-Based Optimization of the Third Generation Type II Macrocycle TRK Inhibitors with Improved Activity against Solvent-Front, xDFG, and Gatekeeper Mutations.Semantic proximity Read

Selective type II TRK inhibitors overcome xDFG mutation mediated acquired resistance to the second-generation inhibitors selitrectinib and repotrectinibSemantic proximity Read

Discovery of novel diarylurea derivatives as potent type II TRK inhibitors for combating multiple acquired resistant mutants.Semantic proximity Read

Discovery of the First Highly Selective and Broadly Effective Macrocycle-Based Type II TRK Inhibitors that Overcome Clinically Acquired Resistance.Semantic proximity Read

JND4135, a New Type II TRK Inhibitor, Overcomes TRK xDFG and Other Mutation Resistance In Vitro and In Vivo.Semantic proximity Read

Exploring the kinase-inhibitor fragment interaction space facilitates the discovery of kinase inhibitor overcoming resistance by mutations.Semantic proximity Read

Larotrectinib, a selective tropomyosin receptor kinase inhibitor for adult and pediatric tropomyosin receptor kinase fusion cancersSemantic proximity Read

Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of TRK fusion cancerSemantic proximity Read

TRK inhibitor activity and resistance in TRK fusion-positive cancers in adults.Semantic proximity Read

Switch type I to type II TRK inhibitors for combating clinical resistance induced by xDFG mutation for cancer therapy.Semantic proximity Read